Atea Pharmaceuticals (AVIR) Current Assets (2019 - 2026)

Atea Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $263.2 million for Q1 2026.

• In Q1 2026, Current Assets fell 39.31% year-over-year to $263.2 million; the TTM figure through Mar 2026 stood at $263.2 million (down 39.31% YoY), while the FY2025 annual figure was $311.0 million, down 32.74% from the prior year.
• Current Assets was $263.2 million for Q1 2026 at Atea Pharmaceuticals, down from $311.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $713.2 million in Q1 2022 to a low of $263.2 million in Q1 2026.
• Historically, Current Assets has averaged $525.1 million across 5 years, with a median of $548.8 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Current Assets retreated 9.95% in 2023, then tumbled 39.31% in 2026.
• A 5-year view of Current Assets shows it stood at $660.9 million in 2022, then slipped by 10.66% to $590.5 million in 2023, then dropped by 21.7% to $462.4 million in 2024, then slumped by 32.74% to $311.0 million in 2025, then retreated by 15.37% to $263.2 million in 2026.
• The last three Current Assets figures came in at $263.2 million (Q1 2026), $311.0 million (Q4 2025), and $336.1 million (Q3 2025), per Business Quant data.